Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

March 2015

Volume 2  Issue 1

____________________________________________________________________________________________________

Case Report
Uremic Toxins Deregulate the Expression of miR-29a and miR-29b in Endothelial Cells

JOKAZAKI Hirokazu, METZINGER-LE MEUTH Valerie, M’BAYA-MOUTOULA Eleonore, TAIBI Fatiha, MASSY Ziad A and METZINGER Laurent

 Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD). The uremic toxins that accumulate in CKD patients as a result of impaired kidney function are involved in vascular dysfunction and increase the already high risk of cardiovascular mortality in this population. Although recent studies suggest that dysregulation of the microRNA (miRNA)-29 family is associated with impaired vascular function, the effect of uremia on miR-29 expression in the vascular wall has yet to be characterized.

                                                                                                                                                                                                                              Full textDownload PDF

____________________________________________________________________________________________________

Research Article
Meropenem Plus Tobramycin Followed by Meropenem Plus Vancomycin for Treating Peritoneal Dialysis-Related Peritonitis ---Single Center Experience---

Kazuhiro Kobayashi, Naofumi Ikeda, Tsutomu Inoue, Yusuke Watanabe, Hiromichi Suzuki1*

Peritonitis is a serious complication for patients on peritoneal dialysis (PD), and is the primary reason for switching from PD to hemodialysis (HD). Appropriate use of antibiotics remains central to the treatment of peritonitis. The International Society for Peritoneal Dialysis (ISPD) published guidelines in 2000 which were updated in 2005. Alternatively, first generation cephalosporin plus aminoglycosides can be immediately applied empirically while awaiting the results of PD drainage culture.

                                                                                                                                                                                                                              Full textDownload PDF

____________________________________________________________________________________________________

Research Article
Living Kidney Donation: What’s the Risk?

Judy Tan* and MadhavC Menon

Kidney transplantation is currently the treatment of choice for end-stage renal disease (ESRD) in terms of survival and quality of life compared with other renal . In certain developing countries, it may be the only feasible treatment option for patients with ESRD given the financial burden of maintenance dialysis. As of June 2013, approximately 108,000 patients were registered on the kidney transplant waiting list at the United Network for Organ Sharing (UNOS) in the United States.

                                                                                                                                                                                                                              Full textDownload PDF

____________________________________________________________________________________________________

Case Series 
Systematic Employment of Laparoscopic Decortication for Maximal Pain Control in Polycystic Kidney Disease

Neetika Garg, MD*, Andrew A. Wagner, MD, Theodore I. Steinman, MD

More than 60 percent of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) experience chronic abdominal or flank pain over the course of their lifetime. Individual enlarging cysts can cause pain through stretching the renal capsule and/or compression of surrounding structures. This pain is most often localized to the anterior abdomen. The usual strategy with laparoscopic cyst decortication (LCD) has been to excise/unroof as many cysts close to the surface of the kidney as possible.

                                                                                                                                                                                                                              Full textDownload PDF

____________________________________________________________________________________________________

Review Article
Maintenance of Stable Hemoglobin Levels and Improvement of Iron Utilization in Hemodialysis Patients after Switching from Short to Long Acting Erythropoiesis Stimulating Agents

Hiromichi Suzuki* and Saitama Anemia Research Group

The introduction of erythropoiesis-stimulating agents (ESAs) improved the treatment strategy for anemia in patients with end-stage renal disease (ESRD). However, treatments with ESAs have occasionally been reported to result in fluctuation of hemoglobin (HB) levels in patients receiving hemodialysis (HD). This was attributed to the relatively short half-life, e.g., up to 9 hours for epoetin alfa or beta and approximately 25 hours for darbepoietin alfa. This limitation in clinical practiceneeds a potential ESA with a longer half-life. A continuous erythropoietin receptor activator (C.E.R.A.) is the first compound of a novel class of ESAs with a long half-life (approximately 130 hours) demonstrated by pharmacokinetic studies.

                                                                                                                                                                                                                              Full textDownload PDF

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398